Featured Story

  • Consort Medical strikes $374M deal to buy Aesica

    Consort Medical has placed a big bet on the convergence of drug and device production services, striking a £230 million ($374 million) deal to buy European contract manufacturer Aesica Pharmaceuticals. 

Apotex tries to 'set the record straight' after Health Canada quarantine request

The three-way spat between Health Canada, local media and Apotex is rumbling on. Late last week Health Canada won an equivocal thumbs-up from the media for its move to quarantine products from one of Apotex's Indian plants, only for the generic drugmaker to hit back with a press release to "set the record straight."

Strides and Shasun plan merger to create big, 'de-risking' production network

With a string of regulatory actions against manufacturers showing the dangers of relying heavily on one production plant, India's Strides Arcolab and Shasun Pharmaceuticals plan to merge to spread the risk.

FDA warns of contaminated Chinese meds after toddler suffers lead poisoning

The problem of contaminated cold remedies has once again surfaced in the U.S. More than seven years after diethylene glycol put authorities on high alert, a toddler in New York has suffered from lead poisoning after taking a Chinese cold remedy.

Report: Indian government to take legal action over drug quality paper

The Indian government has begun legal action against think tank the American Enterprise Institute (AEI) over a paper on drug quality, The Times of India reports.

Merck KGaA deal for Sigma-Aldrich gets it some specialty manufacturing capacity

Merck KGaA may have struggled getting new drug products to market, but its $17 billion buyout of Sigma-Aldrich will allow it to help others, as well as itself, in that endeavor.


From Our Sister Sites


The earliest awards from the U.S. National Institutes of Health in support of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, totaling $46 million in fiscal 2014, have been disclosed. The funding goes to more than 100 investigators in 15 locations in the U.S. and three nations.


Investors were pleased that TransEnterix scored a few more quarters' worth of runway in a $25 million debt deal, sending shares up almost 7% in early trading. The minimally invasive surgical company expects to submit a 510(k) for its SurgiBot by year end.